1. Hyuna Sung et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in185 Countries,” CA: A Cancer Journal for Clinicians n/a, no. n/a, accessed February 7, 2021, https:///10.3322/caac.21660.
2. “Targeted Therapy for Cancer - National Cancer Institute,” cgvArticle, August 15, 2014, nciglobal,ncienterprise,https://www./about-cancer/treatment/types/targeted-therapies.
3. William N. Hait, “Targeted Cancer Therapeutics,” Cancer Research 69, no. 4 (February 15, 2009): 1263–67,https:///10.1158/0008-5472.CAN-08-3836.
4. Lei Zhong et al., “Small Molecules in Targeted Cancer Therapy: Advances, Challenges, and Future Perspectives,” SignalTransduction and Targeted Therapy 6, no. 1 (2021): 1–48, https:///10.1038/s41392-021-00572-w.
5. “Herceptin (Trastuzumab) FDA Approval History,” Drugs.com, accessed January 10, 2022,https://www./history/herceptin.html.
6. “Iressa (Gefitinib) FDA Approval History - Drugs.Com,” accessed January 10, 2022, https://www./history/iressa.html.
7. Raju K. Vaddepally et al., “Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with theLevel of Evidence,” Cancers 12, no. 3 (March 20, 2020), https:///10.3390/cancers12030738.
8. P. Zatloukalová et al., “[The Role of PD-1/PD-L1 Signaling Pathway in Antitumor Immune Response],” Klinicka Onkologie: CasopisCeske a Slovenske Onkologicke Spolecnosti 29 Suppl 4, no. Suppl 4 (Fall 2016): 72–77.
9. Hyun Tae Lee et al., “Molecular Mechanism of PD-1/PD-L1 Blockade via Anti-PD-L1 Antibodies Atezolizumab and Durvalumab,”Scientific Reports 7 (July 17, 2017), https:///10.1038/s41598-017-06002-8.
10. Hyun Tae Lee, Sang Hyung Lee, and Yong-Seok Heo, “Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, andCTLA-4 in Immuno-Oncology,” Molecules 24, no. 6 (March 26, 2019), https:///10.3390/molecules24061190.
11. Francesco Passiglia et al., “<p>Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on theHorizon?</P>,” ImmunoTargets and Therapy 10 (February 5, 2021): 9–26, https:///10.2147/ITT.S253581.
12. “Genentech’s Novel Anti-TIGIT Tiragolumab Granted FDA Breakthrough Therapy Designation in Combination With Tecentriq for PD-L1-High Non-Small Cell Lung Cancer,” January 5, 2021, https://www./news/home/20210104005887/en/Genentech%E2%80%99s-Novel-Anti-TIGIT-Tiragolumab-GrantedFDA-Breakthrough-Therapy-Designation-in-Combination-With-Tecentriq-for-PD-L1-High-Non-Small-Cell-Lung-Cancer
13. Johann S. Bergholz et al., “Integrating Immunotherapy and Targeted Therapy in Cancer Treatment: Mechanistic Insights and Clinical Implications,” Clinical Cancer Research 26, no. 21 (November 1, 2020): 5557–66, https:///10.1158/1078-0432.CCR-19-2300.
14. Deric L. Wheeler, Emily F. Dunn, and Paul M. Harari, “Understanding Resistance to EGFR Inhibitors—Impact on Future Treatment
Strategies,” Nature Reviews. Clinical Oncology 7, no. 9 (September 2010): 493–507, https:///10.1038/nrclinonc.2010.97.
15. Remah Ali and Michael K. Wendt, “The Paradoxical Functions of EGFR during Breast Cancer Progression,” Signal Transduction
and Targeted Therapy 2, no. 1 (2017): 1–7, https:///10.1038/sigtrans.2016.42.
16. “Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in
Non-Small-Cell Lung Carcinoma Treatments,” PLOS ONE 10, no. 5 (May 20, 2015): e0128360,
https:///10.1371/journal.pone.0128360.
17. H. Harjunpää and C. Guillerey, “TIGIT as an Emerging Immune Checkpoint,” Clinical & Experimental Immunology 200, no. 2
(2020): 108–19, https:///10.1111/cei.13407.
18. Wenting Zhang et al., “Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis,” Frontiers in Immunology 11 (2020),
https:///10.3389/fimmu.2020.00018.
19. Zatloukalová et al., “[The Role of PD-1/PD-L1 Signaling Pathway in Antitumor Immune Response].”
20. Theresa L. Whiteside and Ronald B. Heberman, “Antitumor Effector Cells in Humans,” Holland-Frei Cancer Medicine. 6th Edition,
2003, https://www.ncbi.nlm./books/NBK13070/.
21. “TIGIT - an Overview | ScienceDirect Topics,” accessed March 29, 2021,
https://www./topics/biochemistry-genetics-and-molecular-biology/tigit.
22. Fanqiao Meng et al., “Overexpression of TIGIT in NK and T Cells Contributes to Tumor Immune Escape in Myelodysplastic
Syndromes,” Frontiers in Oncology 10 (2020), https:///10.3389/fonc.2020.01595.
23. Xiaowan Yin et al., “Expression of the Inhibitory Receptor TIGIT Is Up-Regulated Specifically on NK Cells With CD226 Activating
Receptor From HIV-Infected Individuals,” Frontiers in Immunology 9 (2018), https:///10.3389/fimmu.2018.02341
